$143.43
-15.49-9.75%
Last update: Oct 30, 7:40 PM
GRAIL Inc (GRAL) Stock Price, Quote, News & History
GRALNASDAQ
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
You can purchase shares of GRAIL (NASDAQ:GRAL) through any online brokerage.
Other companies in GRAIL’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
GRAIL has a consensus price target of $119.80.
The stock price for GRAIL (NASDAQ: GRAL) is $144 last updated October 30, 2026 at 7:40 PM EDT.
There are no upcoming dividends for GRAIL.
GRAIL does not have any upcoming earnings scheduled.
There is no upcoming split for GRAIL.
GRAIL is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in...
